US EditionIdentiv Reports Third Quarter 2025 Financial Results
Avidity Biosciences reported a GAAP net loss of $174 million and strengthened its RNA therapeutic pipeline with FDA Breakthrough Therapy designation for del-zota.
- On Nov. 10, 2025, Avidity issued third-quarter 2025 results and disclosed a planned $147.6 million equity raise to support clinical programs.
- After a pre-BLA meeting in October 2025, the FDA-aligned pathway was supported by positive program data, the company said.
- Avidity booked a $170.5 million collaboration milestone from Eli Lilly and Company and reported a strong cash position of ~$1.9 billion.
- The company plans to spin off early-stage programs into SpinCo and has a BLA submission planned for 2026, Avidity announced.
- Management framed the AOC platform as having transformative potential for rare diseases, but company management warned forward-looking caution involves risks and actual results may differ materially.
137 Articles
137 Articles
newportvermontdailyexpress.com
M-tron Industries, Inc. Reports Third Quarter 2025 Results
Revenues were $14.2 million for the three months ended September 30, 2025Gross margin was 44.3% for the three months ended September 30, 2025Net income per diluted share was $0.63 for the three months ended September 30, 2025Backlog was $58.8 million…
Mattr Announces Third Quarter 2025 Results
TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and nine months ended September 30, 2025. This press release should be read in conjunction…
Tuniu to Report Third Quarter 2025 Financial Results on December 5, 2025
NANJING, China, Nov. 12, 2025 /PRNewswire/ -- Tuniu Corporation (NASDAQ:TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that it plans to release its unaudited financial results for the third quarter ended September 30,…
Coverage Details
Bias Distribution
- 51% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium